Mild Cognitive ImpairmentCOMETNCT05332522
Computerized Memory Enhancing Treatment in MCI
A study testing Neuroplasticity-based Computerized Cognitive Remediation in people with Mild Cognitive Impairment, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to improve memory function in patients with Mild Cognitive Impairment (MCI). Read more about this study
- Who is it for?
- Ages 55 to 85 years
- Conditions the study is for
- Mild Cognitive Impairment
- What is being tested?
- Neuroplasticity-based Computerized Cognitive Remediation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Aug 2022to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a subjective memory concern as reported by participant, study partner or clinician
- Be between 55 and 85 years of age (inclusive)
- Clinical Dementia Rating16 Global score of 0.5
- Mini-Mental State Exam score between 22-30 (inclusive)
- General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease dementia cannot be made by the site clinician at the time of the screening visit
- Geriatric Depression Scale score of less than or equal to 14
Show all 11Show fewer
- Study Partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to most visits to answer questions about the participant
- Adequate visual and auditory acuity to allow neuropsychological testing
- Good general health with no additional diseases/disorders expected to interfere with the study
- Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile)
- Completed six grades of education or has a good work history Fluent in and able to read English.
Who cannot join
- Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
- Major depression, bipolar disorder as described in DSM-V within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol
- History of schizophrenia (DSM V criteria)
- History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
- Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results, or the participant's ability to participate in the study.
- Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
Show all 9Show fewer
- Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening,
- Residence in a skilled nursing facility
- Participants whom the Principal Investigator deems to be otherwise ineligible.
Trial locations and contacts
1 site in 1 country.
United States1 site
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
About this study
Official title: A Pilot and Feasibility Study of Computerized Cognitive Remediation to Improve Cognitive and Functional Performance in Adults With Mild Cognitive Impairment
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to improve memory function in patients with Mild Cognitive Impairment (MCI).
Read the detailed description
There is currently no efficacious treatment to delay or prevent decline from mild cognitive impairment (MCI) to dementia. Despite major technological advances, from refined animal models, novel molecular approaches, and in vivo biological marker development, discoveries have not translated into effective treatments to prevent decline. A potential alternative approach is cognitive training, however previous studies on memory-focused training have had mixed success in MCI groups, and longer-term improvement has not been observed. A more effective strategy may be to target the deterioration of networks that support memory function, for instance the frontoparietal cortical regions of the cognitive control network (CCN) which are important for higher-order cognitive functions such as planning and switching effectively. These networks become increasingly vital during aging and cognitive decline, as frontal lobe activation acts as a compensatory mechanism for lower-level structural deficits. The present study proposes a novel cognitive enhancement strategy, informed by clinical, behavioral, and neurobiological data suggesting that strengthening these frontal area connections in the CCN may compensate for the deficits in circuitry associated with MCI.
Neuroplasticity-based computerized cognitive remediation (nCCR) is a cognitive enhancement strategy that aims to alter disease-related changes in brain function through the induction of neuroplasticity in clinically relevant networks, subsequently resulting in improved cognitive performance. Neuroplasticity refers to the brain's ability to modify, change, and adapt both structure and function and can be induced through the use of network-specific techniques expressed even in the abnormally aging brain. nCCR involves an intensive, attention-demanding schedule of computerized cognitive training that is both individually adaptive and rewarding to participants. nCCR uses bottom-up and top-down training strategies that have been proven in both preclinical and clinical models to induce neuroplasticity and cognitive enhancement. "Bottom-up" perceptual training in both animal models and older adults has been observed to improve both targeted (perceptual discrimination) and other cognitive functions (working memory). "Top-down" activation of the CCN via nCCR has been shown to improve targeted functions (cognitive flexibility), and also to transfer this improvement to other, untrained skills (episodic memory) in older adults. Prior studies in late-life depression show that nCCR can transfer improvements from targeted to untrained processes, which may lead to a functional improvement in multiple cognitive domains. The researchers propose to test whether in MCI patients, boosting CCN activation may produce enhancement to deficits that are characteristic of the syndrome such as memory and attention.
The proposed study utilizes an nCCR intervention strategy which has successfully shown reductions in executive dysfunction in adults with geriatric depression, and recently been applied by our group to participants suffering from chemotherapy-related cognitive impairment (CRCI) with promising preliminary results showing improvements in both subjective ratings of performance and objective cognitive performance. The proposed study aims to use this nCCR intervention to examine the potential benefits in MCI patients and to obtain pilot data for a larger randomized clinical trial. Before and after the treatment period the researchers will examine self-report and objective measures of performance and utilize EEG to assess physiological changes associated with neuroplasticity induced by nCCR treatment.
- Conditions
- Mild Cognitive Impairment
- Being tested
- Neuroplasticity-based Computerized Cognitive Remediation
- Keywords
- nCCR, MCI, Mild Cognitive Impairment, Neuroplasticity-based computerized cognitive remediation
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuroplasticity-based Computerized Cognitive RemediationBehavioural
The nCCR has two major components: Bottom up and Top down training.
Bottom up" training: The training includes selected tasks from "Brain HQ", a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.
Top down training": We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These "Top Down" Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.
| Study group | Role | What they receive |
|---|---|---|
| Neuroplasticity-based Computerized Cognitive Remediation | Experimental | Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation Receives: Behavioral: Neuroplasticity-based Computerized Cognitive Remediation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate completion rates of nCCR
Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment.
Measured: 2 years
Evaluate visit frequency throughout nCCR treatment
Assess the frequency of visits during nCCR treatment
Measured: Through study completion, an average of 6 weeks.
Evaluate visit duration throughout nCCR treatment
Assess the duration of visits during nCCR treatment
Measured: Through study completion, an average of 6 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2022
- Study start9 Aug 2022
- Primary completion31 Jul 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single Group Assignment A single-arm, open label design; All analyses are pre-post, with participants serving as their own controls.
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alexander Christian Conley, Vanderbilt University Medical Center
- Investigators
- Alexander C Conley, PhD, Principal investigator, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05332522
- Sponsor's protocol ID
- 212375
- Acronym
- COMET
- Status last verified
- Feb 2025
- First submitted
- 8 Apr 2022
- Last updated
- 11 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot and Feasibility Study of Computerized Cognitive Remediation to Improve Cognitive and Functional Performance in Adults With Mild Cognitive Impairment
- ClinicalTrials.gov ID
- NCT05332522
- Acronym / sponsor ID
- COMET / 212375
- Conditions
- Mild Cognitive Impairment
- Keywords
- nCCR, MCI, Mild Cognitive Impairment, Neuroplasticity-based computerized cognitive remediation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 9 Aug 2022 (actual)
- Primary completion
- 31 Jul 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 18 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to improve memory function in patients with Mild Cognitive Impairment (MCI).
Detailed description
There is currently no efficacious treatment to delay or prevent decline from mild cognitive impairment (MCI) to dementia. Despite major technological advances, from refined animal models, novel molecular approaches, and in vivo biological marker development, discoveries have not translated into effective treatments to prevent decline. A potential alternative approach is cognitive training, however previous studies on memory-focused training have had mixed success in MCI groups, and longer-term improvement has not been observed. A more effective strategy may be to target the deterioration of networks that support memory function, for instance the frontoparietal cortical regions of the cognitive control network (CCN) which are important for higher-order cognitive functions such as planning and switching effectively. These networks become increasingly vital during aging and cognitive decline, as frontal lobe activation acts as a compensatory mechanism for lower-level structural deficits. The present study proposes a novel cognitive enhancement strategy, informed by clinical, behavioral, and neurobiological data suggesting that strengthening these frontal area connections in the CCN may compensate for the deficits in circuitry associated with MCI.
Neuroplasticity-based computerized cognitive remediation (nCCR) is a cognitive enhancement strategy that aims to alter disease-related changes in brain function through the induction of neuroplasticity in clinically relevant networks, subsequently resulting in improved cognitive performance. Neuroplasticity refers to the brain's ability to modify, change, and adapt both structure and function and can be induced through the use of network-specific techniques expressed even in the abnormally aging brain. nCCR involves an intensive, attention-demanding schedule of computerized cognitive training that is both individually adaptive and rewarding to participants. nCCR uses bottom-up and top-down training strategies that have been proven in both preclinical and clinical models to induce neuroplasticity and cognitive enhancement. "Bottom-up" perceptual training in both animal models and older adults has been observed to improve both targeted (perceptual discrimination) and other cognitive functions (working memory). "Top-down" activation of the CCN via nCCR has been shown to improve targeted functions (cognitive flexibility), and also to transfer this improvement to other, untrained skills (episodic memory) in older adults. Prior studies in late-life depression show that nCCR can transfer improvements from targeted to untrained processes, which may lead to a functional improvement in multiple cognitive domains. The researchers propose to test whether in MCI patients, boosting CCN activation may produce enhancement to deficits that are characteristic of the syndrome such as memory and attention.
The proposed study utilizes an nCCR intervention strategy which has successfully shown reductions in executive dysfunction in adults with geriatric depression, and recently been applied by our group to participants suffering from chemotherapy-related cognitive impairment (CRCI) with promising preliminary results showing improvements in both subjective ratings of performance and objective cognitive performance. The proposed study aims to use this nCCR intervention to examine the potential benefits in MCI patients and to obtain pilot data for a larger randomized clinical trial. Before and after the treatment period the researchers will examine self-report and objective measures of performance and utilize EEG to assess physiological changes associated with neuroplasticity induced by nCCR treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single Group Assignment A single-arm, open label design; All analyses are pre-post, with participants serving as their own controls.
| Arm | Type | Receives |
|---|---|---|
| Neuroplasticity-based Computerized Cognitive Remediation | Experimental | Behavioral: Neuroplasticity-based Computerized Cognitive RemediationParticipants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation |
Who may qualify
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Have a subjective memory concern as reported by participant, study partner or clinician
- Be between 55 and 85 years of age (inclusive)
- Clinical Dementia Rating16 Global score of 0.5
- Mini-Mental State Exam score between 22-30 (inclusive)
- General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease dementia cannot be made by the site clinician at the time of the screening visit
Key exclusion criteria (9 listed)
- Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
- Major depression, bipolar disorder as described in DSM-V within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol
- History of schizophrenia (DSM V criteria)
- History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
- Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results, or the participant's ability to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuroplasticity-based Computerized Cognitive RemediationThe nCCR has two major components: Bottom up and Top down training. Bottom up" training: The training includes selected tasks from "Brain HQ", a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding. Top down training": We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These "Top Down" Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization. | Behavioural | Neuroplasticity-based Computerized Cognitive Remediation |
Primary outcome
Evaluate completion rates of nCCR
Time frame: 2 years
Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment.
Evaluate visit frequency throughout nCCR treatment
Time frame: Through study completion, an average of 6 weeks.
Assess the frequency of visits during nCCR treatment
Evaluate visit duration throughout nCCR treatment
Time frame: Through study completion, an average of 6 weeks.
Assess the duration of visits during nCCR treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Loneliness as Risk Factor for Dementia
Mild Cognitive Impairment (MCI), Dementia (Diagnosis)
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer's Disease
Recruiting
Combating Alzheimer's Through Sleep and Exercise
Dementia, Mild Cognitive Impairment (MCI)
Active, not recruiting
EFFECTS OF AN OUTDOOR MAT PILATES PROGRAM ON NEUROPHYSIOLOGICAL INDICATORS OF ELDERLY INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT
Cognition Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexander C Conley, PhD principal investigator
Vanderbilt University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuroplasticity-based Computerized Cognitive Remediation in people with Mild Cognitive Impairment, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate completion rates of nCCR (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2025.